Case Reports in Nephrology

Case Reports in Nephrology / 2018 / Article

Case Report | Open Access

Volume 2018 |Article ID 3697120 |

Rishi Raj, Aasems Jacob, Ajay Venkatanarayan, Mohankumar Doraiswamy, Manjula Ashok, "Severe Symptomatic Hyponatremia Secondary to Escitalopram-Induced SIADH: A Case Report with Literature Review", Case Reports in Nephrology, vol. 2018, Article ID 3697120, 7 pages, 2018.

Severe Symptomatic Hyponatremia Secondary to Escitalopram-Induced SIADH: A Case Report with Literature Review

Academic Editor: Yoshihide Fujigaki
Received01 Jul 2018
Accepted19 Aug 2018
Published05 Sep 2018


Hyponatremia is a well-known medication related side effect of selective serotonin reuptake inhibitors; despite its association with escitalopram, the newest SSRI is very rare. We did a review of literature and came across only 14 reported case of this rare association of SIADH with escitalopram. We hereby report a case of a 93-year-old female who presented with generalized tonic-clonic seizure and was diagnosed with severe hyponatremia due to escitalopram-induced syndrome of inappropriate antidiuretic hormone secretion (SIADH). With this article, we want to emphasize clinicians about this rare side effect of escitalopram use and look for the risk factors leading to SIADH.

1. Background

The syndrome of inappropriate antidiuretic hormone secretion (SIADH) is a well-known cause of hyponatremia. It is a diagnosis of exclusion and can be secondary to pulmonary disorders, infections, malignant diseases, central nervous system disorders, or drugs [1]. Selective serotonin reuptake inhibitors (SSRIs) are a well-known cause of SIADH with a threefold increased risk compared to other antidepressants [2]. Hyponatremia from escitalopram, one of the newest SSRI is rare with only few reported cases in literature. Here, we report a case of severe hyponatremia which was associated with escitalopram. The importance of the report lies in the fact that SSRIs are one of the most widely used antidepressants and it is imperative for the clinicians to be more widely aware of the life-threatening nature of the side effect of this seemingly benign medication.

2. Case Presentation

A 93-year-old Caucasian female was brought to emergency room for gradual decline in mental status over a course of one week. Her past medical history was significant for coronary artery disease, hypertension, diabetes mellitus, hyperlipidemia, and mild cognitive dysfunction. Her medications included aspirin 81 mg daily, metoprolol 25 mg daily, amlodipine 10 mg daily, and atorvastatin 20 mg daily. Four days prior to the onset of symptoms, she was started on escitalopram 10 mg daily by her primary care physician for newly diagnosed depression. She had a routine blood work immediately prior to the outpatient visit and on retrospective review was found to have a serum sodium level of 136 mEq/L. Patient developed drowsiness and inability to maintain conversation after four days of starting escitalopram. Her mental status continued to gradually decline over the course of next few days and on the day of presentation, which was seven days from the onset of symptoms, she was noted to have intermittent severe agitation. She did not have fever, chills, neck rigidity, myalgia, recent trauma, or fall. There was no reported seizure activity or loss of consciousness. At the time of admission, patient was afebrile, blood pressure was 134/57 mm Hg, pulse rate was 75 beats/min, and respiratory rate of 18 and saturating was 99% on room air. Her BMI was 27.1. She was noted to be lethargic and was only responsive to painful stimuli. Mucous membranes were moist, and the skin turgor was intact. Her GCS score was 7 (E2V1M4). Neurological examination was negative for any gross focal neurological deficits. The rest of the physical examination was unremarkable. While, in the emergency room, patient was noted to have generalized tonic-clonic seizure which was controlled with a single dose of intravenous lorazepam 1 mg. Initial laboratory investigation results are presented in Table 1, along with reference range values. Notably, patient’s serum osmolality was 234mosm/kg (normal range: 275–295 mosm/kg), urine osmolality was 468 mosm/kg, serum sodium was 105 mEq/L (normal range: 135–145 mEq/L), and urinary sodium was 68 mEq/L (normal range 25-150 mEq/L). Her thyroid-stimulating hormone (TSH) and early morning free cortisol were 0.8 μIU/mL (normal range 0.5-5.0 μIU/mL) and 49.2 μg/dL (normal range 1-75 μg/dL), respectively. Chest X-ray as well as CT Head without contrast were unremarkable.

Laboratory TestLevelsReference Range

Serum Sodium105 mEq/L135 –145 mEq/L
Serum Chloride74 mEq/L99-109 mEq/L
Serum Osmolality234mosm/kg275–295 mosm/kg
Serum Creatinine0.69 mg/dL0.40-1.10 mg/dL
Blood Urea Nitrogen (BUN)10 mg/dL5-21 mg/dL
Urine Sodium68 mEq/L25-150 mEq/L
Urine Chloride75 mEq/L75-170 mEq/L
Urine Osmolality468 mosm/kg50-1400 mosm/kg
Morning Cortisol49.2 mcg/dL1.0-75.0 mcg/dL
Thyroid Stimulating Hormone (TSH)0.86 mcIU/mL0.5- 5.0 mcIU/mL

3. Diagnosis

Based on her clinical findings of witnessed seizure, laboratory findings of severe hyponatremia, hypoosmolality, elevated urine osmolality, and elevated urinary sodium in the presence of normal adrenal and thyroid function, a diagnosis of acute severe symptomatic hypotonic hyponatremia or SIADH was made based on the diagnostic criteria (Table 2). The current symptoms were attributed to initiation of escitalopram due to the temporal relation.

Essential criteria

1. True plasma hypoosmolality (<275 mOsm/kg H2O)
2. Inappropriate urinary response to hypoosmolality (urine osmolality >100 mOsm/kg H2O)
3. Euvolemia; no edema, ascites, or signs of hypovolemia
4. Elevated urine sodium (>30 mEq/L) during normal sodium and water intake
5. No other causes of euvolemic hyponatremia

Supplemental criteria

1. No significant increase in serum sodium after volume expansion, but improvement with fluid restriction.
2. Unable to excrete >80% of a water load (20 cc/kg) in 4 hours and/or failure to achieve urine osmolality <1mOsm/kg H2O

4. Treatment

Escitalopram was discontinued on the day of admission. She was started on 3% hypertonic saline at 20 ml/hr with frequent monitoring of her sodium levels with a goal sodium correction of less than 10 mEq/L in 24 hrs. Patient was put on water restriction to less than one liter per day. She was also given 2 doses of Tolvaptan 15 mg on Day 3 and Day 5 of hospitalization. Patient did not have any further episodes of seizures. Her sodium levels started to trend up and her sodium levels became normal on the 6th day of hospitalization (Figure 1). The patient was finally discharged home on Day 6. Sodium levels on discharge were 135 mEq/L. She was discharged without any SSRI. Repeat sodium levels on 1 week and 2 weeks were 138 mEq/L and 142 mEq/L, respectively. She was eventually started on Mirtazapine 15 mg at bedtime on outpatient follow-up and her sodium levels remained within normal range at 3 and 6 months.

5. Discussion & Review of Literature

SIADH is defined as euvolemic hypotonic hyponatremia (serum sodium level of less than 135mmol/L), inappropriately elevated urine osmolality (usually more than 200 mmol/kg) relative to plasma osmolality, and an elevated urine sodium level (typically greater than 20 mmol/L) with normal renal, adrenal, and thyroid functions. Since Schwartz et al. first described it about 6 decades ago in 1957 in two patients, SIADH now has a long list of potential causes including malignant neoplasms, nonmalignant pulmonary diseases, central nervous system disorders, and drugs. In a single center retrospective study, Shepshelovich et al. compared different drug classes and showed a higher incidence of SIADH with antidepressants mainly SSRIs compared to other drug classes [3]. SSRIs are becoming increasingly leading because of SIADH with a reported incidence of 1 out of 200 patients per year [4]. SSRIs are first-line drugs for the treatment of geriatric depression owing to their safety, easy dose titration, and low rates of anticholinergic and cardiovascular adverse events [5]. Among SSRIs, escitalopram is the newest SSRI and was FDA approved in 2002. It is composed of only (S)-enantiomer of citalopram and inhibits the binding of serotonin (5-HT) to serotonin transporter (SERT), resulting in increased 5-HT concentration in synaptic cleft, which leads to increased binding of 5-HT to postsynaptic receptors causing improvement in the depression symptoms [6]. Experimental studies have revealed that enhanced serotonergic tone result in stimulation of antidiuretic hormone (ADH) secretion resulting in hyponatremia, provided water intake is sufficient [7]. As a matter of fact, since the publication of the above literature, there has been increasingly higher number of reports on escitalopram-induced SIADH. We aimed to identify these cases with detailed characteristics and present an extensive review of SIADH associated with escitalopram use which has not been included in the previous reviews. We reviewed literature published between January 1, 2002, and March 31, 2018, through search on Medline and found fourteen reported cases of SIADH associated with escitalopram use (Table 3). We also went through reference sections of each of these reports to identify other missing articles.

Case ReportAgeSexEscitalopram DoseOnset
Levels (mEq/L)
Presenting SymptomsTreatment givenResolution
Comorbid conditionsMedicationsRemarks

Nashoni et al, 2004 [8]62F10 mg21110SyncopeMedication discontinuation1 weekHypertension, Hyperlipidemia
Atrial fibrillation
Protein C deficiency
Vitamin D
Patient was later treated with Mirtazapine for depression

Nirmalani et al, 2006 [22]50M20 mg28121Weakness
Medication discontinuation
Fluid Restriction
5 daysDepression with Psychotic features,

Adiga et al, 2006 [12]81F10 mg21120Generalized weakness &
Recurrent Falls
Medication discontinuation
Hypertonic saline
1 weekAlzheimer's' disease Hypertension
Alendronic acid
Patient noted to have Renal tubular defect

Grover et al, 2007 [14]67F10 mg28
127DeliriumMedication discontinuation
4 weeksBipolar affective disorder
Diabetes mellitus
Sodium valproate
Patient was later treated with Mirtazapine & Valproate for Moderate depression

Grover et al, 2007 [14]75M10 mg10126SeizuresMedication discontinuation
2 weeksHypertension
Generalized anxiety disorder
Patient was later treated with Mirtazapine for Generalized Anxiety disorder

Covyeou et al, 2007 [13]75FUnknown5116UnknownMedication discontinuation
5 daysHypertensionAmlodipine

Koski et al, 2009 [9]97F5 mg7113
Recurrent Falls & ConfusionMedication discontinuation
Fluid restriction
Hypertonic saline
UnknownHypertension, Anxiety
UTI (diagnosed 1 day prior to hospitalization)
(started 1 day prior to hospitalization)

Tsai et al
2012 [11]
73F10 mg>60
DeliriumMedication discontinuation
Fluid restriction
2 weeks
1 week
Lewy body dementiaTrihexyphenidyl Bethanechol
Failed rechallenge of escitalopram as patient developed Hyponatremia

Pae et al, 2013 [10]47M5 mg2110SeizureMedication discontinuation
4 daysQuadriplegia with Spinal A-V Malformation
No other medication

Soysal et al, 2014 [23]76F10mg28113Confusion
Medication discontinuation
Hypertonic saline
UnknownHypertension Diabetes mellitus, Alzheimer’s disease
Sleep disorder

Diken et al, 2016 [15]59M10 mg7107Confusion, Hallucination, Drowsiness
Medication discontinuation
Fluid restriction
Hypertonic saline
4 daysCOPD
Diabetes mellitus
Aspirin, metoprolol perindopril amiodarone
Spironolactone Hydrochlorothiazide
Recent introduction of hydrochlorothiazide

Parmar et al, 2016 [20]50M10 mg394SeizureMedication discontinuation
5 daysHypertension
Panic disorder
Developed central pontine myelinolysis from rapid correction of sodium

Rawal et al, 2017 [24]54FUnknown4116SeizureMedication discontinuation
Fluid restriction
Salt restriction

Vidyasagar et al, 2017 [25]58FUnknown14107Severe ConstipationMedication discontinuation
High salt diet
Fluid restriction
UnknownSeronegative spondyloarthropathy
Diabetes mellitus
Prednisolone, Hydroxychloroquine

Nashoni et al. reported the first case of hyponatremia associated with escitalopram in 2004 in a 62-year-old female which occurred 3 weeks following initiation of escitalopram [8]. Majority of these reported escitalopram-induced SIADH were in females (64.28%). While age more than 65 years was found to be risk factor for SSRI-induced SIADH [2], this association was not seen with escitalopram, although the number of cases were limited to draw a definitive statistical conclusion. 50% of reported cases were in patients below 65 years of age. The youngest reported case was in a 47-year-old male who presented with seizures within 4 days of initiation of the drug while the oldest patient was a 97-year-old female [9, 10]. The mean serum sodium levels on presentation were 115 mEq/L.

The most common symptoms at presentation included confusion, seizures, and weakness. None of the reported cases had asymptomatic presentation which signifies underreporting of the association between escitalopram and SIADH. Similar to other SSRIs, the risk of hyponatremia is the highest during the first weeks with the earliest onset being within 2 days of starting escitalopram but can also occur even after 2 months of medication initiation [10, 11]. The median time of onset of symptoms was 7 days. Many of the patients reported in the literature were on multiple medications known to cause hyponatremia especially thiazide, proton pump inhibitor, and other psychiatric medications; however, a temporal association was drawn to escitalopram in all the cases [8, 9, 1215]. Diken et al. reported a case of a 59-year-old male who underwent coronary artery bypass graft and developed hyponatremia with sodium levels of 107 mEq/L about 1 week following concomitant use of escitalopram 10 mg once daily and hydrochlorothiazide 50 mg once daily. Interestingly, this particular patient had prior history of use of escitalopram without any side effects [15].

The main modality of management in SIADH is water restriction, although in severe symptomatic cases hypertonic saline (3%) and drugs such as loop diuretics (furosemide), demeclocycline, and vaptans should be used [16]. Water restriction is the most important treatment modality in patients with SIADH. Those who do not respond fully or respond only partially can be treated with salt tablets and diuretics. Demeclocycline has been used previously which lead to acute kidney injury and hence its use has been limited. Vaptans, a selective V2 receptor antagonist (Tolvaptan and Conivaptan) can be safely used for treatment of SIADH in carefully monitored patients [17, 18]. High cost and overcorrection remain a potential risk for vaptans [18]. In all 14 cases, hyponatremia improved after discontinuation of the drug and active treatment for SIADH with fluid restriction and administration of hypertonic saline. However, in our case Tolvaptan was used for correction of hyponatremia. Rapid correction of hyponatremia leads to serious neurologic problems with the most severe including osmotic demyelination syndrome and hence close monitoring of sodium during the treatment of SIADH is of paramount importance [16, 19]. One patient had complication secondary to treatment of hyponatremia resulting in central pontine myelinolysis [20].

In 2012, Tsai et al. reported a case of 73-year-old female with history of dementia with Lewy bodies who developed delirium after being on escitalopram for 2 months. She was found to have serum sodium of 124 mEq/L on presentation. She recovered to baseline within 2 weeks following discontinuation of medication. Her delirium and hyponatremia (122 mEq/L), however, recurred after escitalopram was rechallenged. During the rechallenge phase, she had an early onset of symptomatic hyponatremia at 4 days [11]. This case signifies that rechallenge of escitalopram leads to SIADH with early initiation of the medication. The mean time for normalization of serum sodium levels after discontinuation of escitalopram and active treatment was found to be 5.8 days among the ten reported cases with data on resolution time. Mirtazapine was noted to be a good choice of antidepressant for those patients who developed escitalopram associated SIADH on review of literature [8, 14].

6. Conclusion

Our case highlights the clear association of escitalopram use with SIADH in the absence of any significant medical comorbidity or concomitant drug use. With our literature review of all the published case reports, we could infer that female gender and use of concomitant medication may be the risk factors for SIADH in patients taking escitalopram. However, more data is needed for obtaining meaningful conclusion regarding the risk factors and associations. Hyponatremia in most cases started within first week of treatment and resolved within 2 weeks after discontinuation of the medication. Patients being started on escitalopram and other SSRIs should be informed about this life-threatening adverse effect and the warning signs. Factors leading to overhydration like water intake for urinary tract infections and ingestion of excess water during exercise can lead to precipitation of SIADH [21]. We suggest regular serum electrolyte monitoring in patients receiving escitalopram and always evaluate patients for hyponatremia when presenting with symptoms of weakness, confusion, or seizures. Patient who once developed SIADH on escitalopram should not be ideally rechallenged with the same medication due to risk of causing more severe SIADH and may be started on alternative antidepressants like Mirtazapine.

Conflicts of Interest

The authors have no potential conflicts of interest that are directly relevant to the contents of this report. No sources of funding were used to assist in the preparation of this report.


  1. M. Sahay and R. Sahay, “Hyponatremia: A practical approach,” Indian Journal of Endocrinology and Metabolism, vol. 18, no. 6, p. 760, 2014. View at: Publisher Site | Google Scholar
  2. K. L. Movig, H. G. Leufkens, A. W. Lenderink et al., “Association between antidepressant drug use and hyponatraemia: a case-control study,” British Journal of Clinical Pharmacology, vol. 53, no. 4, pp. 363–369, 2002. View at: Publisher Site | Google Scholar
  3. D. Shepshelovich, A. Schechter, B. Calvarysky, T. Diker-Cohen, B. Rozen-Zvi, and A. Gafter-Gvili, “Medication-induced SIADH: distribution and characterization according to medication class,” British Journal of Clinical Pharmacology, vol. 83, no. 8, pp. 1801–1807, 2017. View at: Publisher Site | Google Scholar
  4. C. Fonzo-Christe and N. Vogt, “Susceptibility of the elderly patient to hyponatremia induced by selective serotonin reuptake inhibitors,” Therapie, vol. 55, no. 5, pp. 597–604, 2000, from. View at: Google Scholar
  5. P. D. Bowen, “Use of Selective Serotonin Reuptake Inhibitors in the Treatment of Depression in Older Adults: Identifying and Managing Potential Risk for Hyponatremia,” Geriatric Nursing, vol. 30, no. 2, pp. 85–89, 2009. View at: Publisher Site | Google Scholar
  6. S. M. Stahl, “Mechanism of action of serotonin selective reuptake inhibitors. Serotonin receptors and pathways mediate therapeutic effects and side effects,” Journal of Affective Disorders, vol. 51, no. 3, pp. 215–235, 1998. View at: Publisher Site | Google Scholar
  7. L. Kovacs and G. L. Robertson, “Syndrome of Inappropriate Antidiuresis,” Endocrinology and Metabolism Clinics of North America, vol. 21, no. 4, pp. 859–875, 1992. View at: Publisher Site | Google Scholar
  8. E. Nahshoni, A. Weizman, D. Shefet, and N. Pik, “A Case of Hyponatremia Associated With Escitalopram,” Journal of Clinical Psychiatry, vol. 65, no. 12, p. 1722, 2004. View at: Publisher Site | Google Scholar
  9. R. R. Koski, J. A. Covyeou, and M. Morissette, “Case Report of SIADH Associated With Escitalopram Use,” Journal of Pharmacy Practice, vol. 22, no. 6, pp. 594–599, 2009. View at: Publisher Site | Google Scholar
  10. C.-U. Pae, G.-Y. Park, S. Im, S. B. Ko, and S.-J. Lee, “Low-dose escitalopram-associated hyponatremia,” Asia-Pacific Psychiatry, vol. 5, no. 2, pp. E90–E90, 2013. View at: Publisher Site | Google Scholar
  11. P. Tsai, H. Chen, S. Liao, M. M. Tseng, and M. Lee, “Recurrent escitalopram-induced hyponatremia in an elderly woman with dementia with Lewy bodies,” General Hospital Psychiatry, vol. 34, no. 1, pp. 101.e5–101.e7, 2012. View at: Publisher Site | Google Scholar
  12. GU. Adiga and TS. Dharmarajan, “Renal tubular defects from antidepressant use in an older adult: an uncommon but reversible adverse drug effect,” Clin Drug Investi, vol. 26, no. 10, pp. 607–611, 2006,;u=drexel_main&amp;id=GALE%7CA199858434&amp;v=2.1&amp;it=r&amp;sid=summon. View at: Google Scholar
  13. J. A. Covyeou and C. W. Jackson, “Hyponatremia Associated with Escitalopram,” The New England Journal of Medicine, vol. 356, no. 1, pp. 94-95, 2007. View at: Publisher Site | Google Scholar
  14. S. Grover, P. Biswas, G. Bhateja, and P. Kulhara, “Escitalopram-associated hyponatremia [4],” Psychiatry and Clinical Neurosciences, vol. 61, no. 1, pp. 132-133, 2007. View at: Publisher Site | Google Scholar
  15. A. I. Diken, A. Yalçinkaya, Ö. Erçen Diken et al., “Hyponatremia due to escitalopram and thiazide use after cardiac surgery,” Journal of Cardiac Surgery, vol. 31, no. 2, pp. 96-97, 2016. View at: Publisher Site | Google Scholar
  16. P. Gross, “Clinical management of SIADH,” Therapeutic Advances in Endocrinology and Metabolism, vol. 3, no. 2, pp. 61–73, 2012. View at: Publisher Site | Google Scholar
  17. H. D. Zmily, S. Daifallah, and J. K. Ghali, “Tolvaptan, hyponatremia, and heart failure,” International Journal of Nephrology and Renovascular Disease, vol. 4, pp. 57–71, 2011. View at: Publisher Site | Google Scholar
  18. M. A. Humayun and I. C. Cranston, “In-patient Tolvaptan use in SIADH: care audit, therapy observation and outcome analysis,” BMC Endocrine Disorders, vol. 17, no. 1, 2017. View at: Publisher Site | Google Scholar
  19. R. H. Sterns, “Treatment of Severe Hyponatremia,” Clinical Journal of the American Society of Nephrology, vol. 13, no. 4, pp. 641–649, 2018. View at: Publisher Site | Google Scholar
  20. P. Arpit, M. Piyali, T. Manjari, and S. Rajesh, “Escitalopram Induced Hyponatremia,” Escitalopram Induc Hyponatremia ASEAN J Psychiatry, vol. 17, no. 2, 2016. View at: Google Scholar
  21. T. Hew-Butler, M. H. Rosner, S. Fowkes-Godek et al., “Statement of the 3rd International Exercise-Associated Hyponatremia Consensus Development Conference, Carlsbad, California, 2015,” British Journal of Sports Medicine, vol. 49, no. 22, pp. 1432–1446, 2015. View at: Publisher Site | Google Scholar
  22. A. Nirmalani, S. L. Stock, and G. Catalano, “Syndrome of Inappropriate Antidiuretic Hormone Associated with Escitalopram Therapy,” CNS Spectrums, vol. 11, no. 06, pp. 429–432, 2006. View at: Publisher Site | Google Scholar
  23. P. Soysal and A. T. Isik, “Severe Hyponatremia Due to Escitalopram Treatment in an Elderly Adult with Alzheimer's Disease,” Journal of the American Geriatrics Society, vol. 62, no. 12, pp. 2462-2463, 2014. View at: Publisher Site | Google Scholar
  24. G. Rawal, R. Kumar, and S. Yadav, “Severe hyponatremia associated with escitalopram,” Journal of Family Medicine and Primary Care, vol. 6, no. 2, p. 453, 2017. View at: Publisher Site | Google Scholar
  25. S. Vidyasagar, K. Rao, M. Verma, AD. Tripuraneni, N. Patil, and D. Bhattacharjee, “Escitalopram induced SIADH in an elderly female: A case study,” Psychopharmacol Bull, vol. 47, pp. 64–67, 2017, View at: Google Scholar

Copyright © 2018 Rishi Raj et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

More related articles

 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.